For the quarter ending 2026-03-31, IBO made $7K in revenue. -$2,287K in net income. Net profit margin of -32671.43%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 7 | -5* | 18 | 7 |
| Cost of revenue | - | 415* | 1 | 11 |
| Sales, general and administrative compensation (inclusive of stock-based compensation) | 1,620 | 113* | 261 | 246 |
| Sales and marketing | 1 | 20* | 2 | 1 |
| Professional fees | 258 | 38* | 234 | 411 |
| Research and development | 46 | 150* | 52 | 75 |
| Depreciation and amortization | 285 | 281* | 288 | 288 |
| Rent and utilities | 19 | 19* | 19 | 18 |
| Loss on disposal of fixed assets | - | -3* | - | - |
| Other operating expenses | 67 | 89* | 109 | 110 |
| Total costs and expenses | 2,296 | 1,125* | 966 | 1,160 |
| Operating loss | -2,289 | -1,130* | -948 | -1,153 |
| Interest income | - | 4* | 3 | 3 |
| Change in fair value of note payable, related party | - | -10,427* | 268 | 12,942 |
| Interest expense | - | 10* | 262 | 260 |
| Interest income | 5 | - | - | - |
| Gain from operations before income taxes | -2,284 | 9,291* | -1,475 | -14,352 |
| Income tax benefit (expense) | - | -2,580* | - | 0 |
| Net gain | -2,284 | 11,871* | -1,475 | -14,352 |
| Loss (income) from operations attributed to noncontrolling interest | 3 | -15* | -5 | -6 |
| Net gain attributable to common stockholders | -2,287 | 11,886 | -1,470 | -14,346 |
| Basic EPS | -0.02 | 0.169 | -0.12 | -1.18 |
| Diluted EPS | -0.02 | -0.095* | -0.12 | -1.18 |
| Basic Average Shares | 107,785,675 | 70,280,547 | 12,185,412 | 12,185,412 |
IMPACT BIOMEDICAL INC. (IBO)
IMPACT BIOMEDICAL INC. (IBO)